logo
Plus   Neg
Share
Email

Novartis: Xolair Confirms Re-treatment Efficacy In CSU Patients

Novartis (NVS) announced new data showing almost 90% of chronic spontaneous urticaria or CSU patients who responded well to initial Xolair (omalizumab) treatment regained symptom control within 12 weeks of Xolair retreatment following a treatment interruption, based on Weekly Urticaria Activity Score (UAS7) criteria.

The OPTIMA Phase IIIb data re-confirmed that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled. Xolair is a targeted therapy that binds to immunoglobulin E or IgE.

CSU is a distressing skin condition that appears spontaneously and causes persistent hives and/or painful deeper swelling of the skin for 6 weeks or more. As per international treatment guidelines, the goal of treatment for CSU is the complete elimination of symptoms.

Novartis noted that Xolair can reduce or eliminate symptoms for CSU patients who have not successfully controlled their symptoms with H1 antihistamine (H1-antagonists) treatment.

Xolair is the first and only approved therapy for CSU patients who show an inadequate response to H1 antihistamines.

The company noted that findings were presented at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland.

Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis, said, "CSU can have a severe impact on quality of life. Its unpredictable nature, combined with the fact that some physicians mistakenly dismiss it as a trivial condition, can mean patients do not get adequate treatment with effective and long-term symptoms control. If for some reason treatment has been interrupted, these data give patients and physicians confidence that it's possible to regain effective symptom control with Xolair."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A $716 billion defense policy bill easily cleared the Senate on Monday, although the legislation must still be reconciled with the version previously approved by the House. The Senate voted 85 to 10 in favor of the National Defense Authorization Act, which authorizes U.S. military spending for fiscal 2019. Voip-Pal.com Inc. has filed a lawsuit against Amazon Inc., accusing Alexa's calling and messaging services of infringing its patents. The lawsuit, filed by Voip-Pal in the U.S. District Court in Nevada, accuses Amazon's Alexa calling and messaging system of using Voip-Pal's patented technologies to direct voice/video calls and voice messages to both Amazon subscribers and non-subscribers. Canada is a step closer to becoming the first G-7 nation to legalize marijuana nationwide after the House of Commons voted to allow recreational use. The bill will now go back to the country's Senate, which had already approved a version of the bill. On Monday, the House of Commons voted 205 to 82 in favor of the Bill C-45, known as the Cannabis Act.
Follow RTT